一项大型研究发现 Kestra的可穿戴除颤器 百分之百有效 以最低程度的假警报 处理危险的心脏节奏 A large study found Kestra's wearable defibrillator 100% effective in treating dangerous heart rhythms with minimal false alarms.

Kestra Medical Technologies(Kestra Medical Technologies)报告说,其ASSURE可穿戴脱颤颤动器的大规模真实研究取得了丰硕成果,显示100%成功治疗危险的心脏节奏和极低的不适当的冲击率。 Kestra Medical Technologies reported strong results from the largest real-world study of its ASSURE wearable defibrillator, showing 100% successful treatment of dangerous heart rhythms and a very low inappropriate shock rate. 涉及21 612名病人的ACE-PAS试验发现,在心脏病发作后的关键恢复阶段,该装置非常有效,94%的病人没有受到假警报。 The ACE-PAS trial, involving 21,612 patients, found the device highly effective during critical recovery periods after heart events, with 94% of patients experiencing no false alarms. 该装置还在一些用户中检测出未经诊断的心脏状况,每天平均穿戴23小时。 The device also detected undiagnosed heart conditions in some users and was worn an average of 23 hours daily. 在2025年美国心脏协会科学会议上提出的研究结果支持在临床实践中更广泛地使用可磨损脱颤器。 Findings, presented at the 2025 American Heart Association Scientific Sessions, support wider use of wearable defibrillators in clinical practice.